Cholangiocarcinoma

This study tests a new drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug aims to break down the mutated protein that helps tumors grow. The trial has two parts: first, finding a safe dose in small groups, then testing that …

This early-phase trial tested a combination of focused radiation and an immunotherapy drug called bintrafusp alfa in just 2 patients with advanced bile duct cancer that had spread. The goal was to find the safest dose and see if the combo could help control the cancer. The study …

This study tests a drug called olaparib in people with advanced cancers (like brain tumors, bile duct cancer, or other solid tumors) that have a specific gene change called IDH1 or IDH2 mutation. The drug works by blocking an enzyme that cancer cells need to grow. About 89 partic…

This study tests whether adding the experimental drug CTX-009 to standard chemotherapy (paclitaxel) helps adults with advanced bile duct, gallbladder, or ampullary cancer that has worsened after one prior treatment. About 168 participants will be randomly assigned to receive eith…

This phase 3 trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy (gemcitabine plus cisplatin) helps people with advanced biliary tract cancer live longer. About 810 participants received either durvalumab or a placebo alongside chemo. The study m…

This phase 2 study tests the drug entrectinib in over 500 people with advanced solid tumors that have specific gene changes (NTRK, ROS1, or ALK fusions). The goal is to see if the drug can shrink tumors and control the disease. Participants have various cancer types, including lu…

This study tests a combination of two drugs (peposertib and avelumab) plus a special type of radiation (hypofractionated) in people with advanced solid tumors or liver/bile duct cancers that have spread. The goal is to find the safest dose and see if the combination can shrink tu…

This early-stage trial tests a new drug called AU409 in 36 people with advanced liver cancers or solid tumors that have spread to the liver. The main goals are to find the safest dose and check for side effects. Researchers will also look for signs that the drug might shrink tumo…

This study tests a combination of four drugs (gemcitabine, cisplatin, quemliclustat, and zimberelimab) as a first treatment for people with advanced biliary tract cancers, including bile duct cancer. The goal is to see if this mix can slow cancer growth and help people live longe…

This study tests a new drug, APL-5125, in adults with advanced solid tumors like colorectal, pancreatic, and ovarian cancer. The goal is to see if the drug is safe and can shrink or control tumors. About 100 participants will receive the drug in two phases to find the best dose a…

This early-stage trial is testing an experimental oral drug, TYRA-200, in people with advanced bile duct cancer (intrahepatic cholangiocarcinoma) and other solid tumors that have specific changes in the FGFR2 gene. The study aims to find a safe and effective dose and to see wheth…

This study tests whether adding the targeted drug binimetinib to standard chemotherapy (mFOLFOX6) can shrink tumors or extend survival in people with advanced biliary tract cancers that have certain genetic changes (MAPK pathway alterations). About 66 participants whose cancer wo…

This study tested two drugs, olaparib and ceralasertib, in 24 people with advanced solid tumors (like bile duct cancer) that have a specific IDH gene mutation. The goal was to see if the combination could shrink or stop the growth of these hard-to-treat cancers. The trial is no l…

This phase 2 trial tests whether adding pevonedistat to standard chemotherapy (carboplatin and paclitaxel) can shrink tumors in people with advanced bile duct cancer that has spread or cannot be removed. About 40 adults whose cancer progressed after gemcitabine-based chemo will r…

This study tests a daily pill called ivosidenib in 220 adults with advanced bile duct cancer that has a specific IDH1 gene mutation and has not responded to prior treatment. The goal is to confirm the drug's safety and effectiveness. Participants take the tablet once daily in 28-…

This phase 3 trial is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy can help people with advanced biliary tract cancer (a type of bile duct cancer). About 142 participants will receive the combination, and researchers will track side effects, s…

This study is for people with advanced or metastatic cancer who have already been taking futibatinib in a previous study and are still benefiting from it. The goal is to keep giving them the drug (alone or with fulvestrant) and watch for any side effects over a longer period. Onl…

This early-stage study tests an oral drug called LY3410738 in people with advanced solid tumors (like bile duct cancer, cartilage cancer, or brain tumors) that have specific IDH1 or IDH2 mutations. The main goal is to find a safe dose and see if the drug can shrink tumors. About …

This trial tests an experimental drug called ST316, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study focuses on tumors that may have abnormalities in a cell signaling pathway called WNT/β-catenin. The…

This early-stage trial is testing a new oral drug called LY4066434, which blocks several types of KRAS proteins that drive cancer growth. The study includes up to 750 people with advanced pancreatic, lung, colorectal, or other solid tumors that have specific KRAS mutations. The d…

This phase 1 trial tests a new method of delivering chemotherapy for people with cancers that have spread to the lining of the abdomen (peritoneal carcinomatosis) from gastrointestinal cancers like colorectal, stomach, or pancreatic cancer. The drug, nanoliposomal irinotecan (Oni…

This global phase 3 trial is testing whether adding the immunotherapy drug rilvegostomig to standard chemotherapy can help prevent biliary tract cancer from coming back after surgery. About 757 people who had their cancer completely removed will receive either rilvegostomig or a …

This Phase 3 trial tests an oral drug called tinengotinib against standard treatments chosen by the doctor for people with advanced bile duct cancer (cholangiocarcinoma) that has a specific genetic alteration (FGFR) and has stopped responding to chemotherapy and an FGFR inhibitor…

This study tests whether combining two drugs, domvanalimab and zimberelimab, can shrink or control advanced liver and bile duct cancers that have stopped responding to earlier treatments. About 58 adults with these cancers will receive the drug combination. The main goal is to se…

This phase 2 trial tests whether combining two drugs—olaparib and durvalumab—can shrink or control solid tumors that have an IDH mutation. The study includes adults with certain brain tumors (glioma) or bile duct cancer (cholangiocarcinoma) that have not responded well to prior t…

This trial tests an experimental drug called TRK-950 in combination with several standard anti-cancer treatments for people with advanced solid tumors, including colorectal, bladder, ovarian, and other cancers. The main goal is to find safe doses and understand side effects. Part…

This phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…

This study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…

This phase 2 trial tests a combination of liver-directed chemotherapy (irinotecan liposome plus 5-FU/LV) with targeted therapy (lenvatinib) and immunotherapy (PD-1 inhibitors) as a first treatment for advanced intrahepatic cholangiocarcinoma, a rare and aggressive bile duct cance…

This early-phase trial tests whether a patient's own immune cells, called tumor-infiltrating lymphocytes (TIL), can shrink advanced bile duct cancers. Four participants receive chemotherapy to prepare their immune system, then an infusion of their own TIL cells plus high-dose ald…

This early-phase trial is testing a combination of two drugs—guadecitabine and durvalumab—in 55 people with advanced liver, pancreatic, bile duct, or gallbladder cancers that have spread. Guadecitabine aims to stop cancer cell growth, while durvalumab helps the immune system atta…

This study tests if washing the abdomen with distilled water or saline right after removing a pancreatic tumor can help patients live longer. About 845 adults having surgery for pancreatic or related cancers are randomly assigned to one of three groups: washing with saltwater, wa…

This early-phase trial tests a new drug called sEphB4-HSA combined with standard chemotherapy in people with advanced or metastatic solid tumors, including head and neck, pancreatic, lung, and gallbladder cancers. The goal is to find the best dose and see if the combination is sa…

This study tests a new medicine called raludotatug deruxtecan in about 160 adults with advanced gastrointestinal cancers (pancreatic, bile duct, gallbladder, colorectal, stomach, or gastroesophageal junction). The drug is designed to attach to cancer cells and deliver a treatment…

This study tests an experimental drug called CGT4859 in people with bile duct cancer or other advanced solid tumors that have specific changes in the FGFR2 or FGFR3 genes. The drug is designed to block these faulty genes and slow tumor growth. About 110 adults who have already tr…

This early-phase study tests a drug called IDH305 in people with advanced cancers that have a specific IDH1R132 mutation. The main goal is to find a safe dose and see if the drug can shrink tumors. About 166 participants will take part.

This study tests a precise type of radiation called SBRT for people with liver cancer or tumors that have spread to the liver. It includes 280 participants with various liver tumor types. The goal is to see how well SBRT controls tumor growth and what side effects occur.

This phase 2 trial is testing a combination of chemotherapy (gemcitabine/cisplatin) plus two targeted drugs (trastuzumab and pembrolizumab) as a first treatment for people with HER2-positive biliary tract cancer that cannot be removed by surgery. The study includes 24 participant…

This program provides futibatinib (TAS-120) to adults with advanced bile duct cancer that has a specific FGFR2 gene change and who have no other treatment options. Participants take one 20 mg pill daily. The goal is to give access to this drug while it is being studied further.

This study is testing a drug called tucatinib combined with other cancer medicines (trastuzumab, chemotherapy, and pembrolizumab) in people with HER2-positive cancers of the digestive system. The main goals are to find safe doses and see what side effects occur. About 40 adults w…

This phase II trial tests a drug called sacituzumab govitecan in 15 people with advanced bile duct cancer that has spread or returned after treatment. The drug works like a smart bomb, attaching to a protein on cancer cells and delivering a toxic payload to kill them. Researchers…

This Phase 2 study is testing a combination of three drugs—nanoliposomal irinotecan, fluorouracil, and leucovorin—in 48 adults with advanced biliary tract cancer that has progressed after initial chemotherapy. The main goal is to see if the treatment can stop the cancer from grow…

This study tests a combined pump and catheter system that delivers chemotherapy directly to the liver in adults with colorectal cancer that has spread to the liver or with bile duct cancer. The main goal is to see if the device is safe. About 100 participants will have the pump i…

This study tests a daily pill called ivosidenib in 12 Japanese patients with advanced bile duct cancer that has an IDH1 mutation and has already been treated with other therapies. The goal is to see if the drug can stop the cancer from growing for at least 6 months. Participants …

This study tests whether adding immunotherapy drugs (durvalumab and tremelimumab) to a type of internal radiation therapy (Y-90 SIRT) can shrink tumors in people with advanced bile duct cancer that has not spread beyond the liver. About 50 adults with this rare liver cancer will …

This study tests a combination of two drugs, atezolizumab and derazantinib, in 27 adults with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer) that has a specific FGFR2 gene change. The goal is to see if the combination shrinks tumors. Participants receive bo…

This early-phase study tests a new oral drug, ABSK121-NX, in people with advanced solid tumors that no longer respond to standard treatments. The main goal is to check safety and find the right dose. About 169 adults will take part, and researchers will also look for any signs th…

This study tests a treatment called irreversible electroporation (IRE) for people with liver cancer who cannot have surgery because their tumors are too close to major blood vessels. IRE uses short, strong electrical pulses to destroy cancer cells without harming nearby blood ves…

This phase 2 trial tests the immunotherapy drug pembrolizumab (Keytruda) in people with 15 types of advanced solid tumors that have worsened after standard treatments. About 1,600 participants receive the drug to see if their tumors shrink or stop growing. The study also looks fo…

This study aimed to test whether a person's own immune cells, modified in a lab to target specific cancer-related mutations (KRAS or TP53), could prevent advanced gastrointestinal cancers from coming back after standard treatment. Participants would have been randomly assigned to…

This study tests whether giving a combination of an immunotherapy drug (toripalimab), a targeted therapy (lenvatinib), and chemotherapy (GEMOX) before surgery can improve outcomes for people with a high-risk type of bile duct cancer. The trial includes 178 patients whose cancer i…

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This study is developing an artificial intelligence system that combines CT/MRI scans, lab results, and radiology reports to help diagnose liver cancer and predict how patients will fare after surgery. The AI aims to distinguish benign from malignant liver lesions and differentia…

This study is testing a new imaging agent called 18F-FSPG to see if it can better detect liver cancer (hepatocellular carcinoma) and other liver tumors compared to standard PET scans. About 110 adults with liver cancer or benign liver tumors will receive the tracer before their s…

This study aimed to compare two different needles used to take tissue samples from solid masses in the pancreas and digestive tract. The goal was to see which needle provides a more accurate diagnosis. The study was planned for adults needing this procedure, but it was withdrawn …

This early study tests a new radioactive tracer called 68Ga-FAPI-46, which targets a protein (FAP) found around many tumors. About 26 people with various cancers will get a PET/CT scan using this tracer to see where it goes in the body. The goal is to learn if this tracer can hel…

This early-phase study looks at whether Emotional Freedom Techniques (EFT) — a practice that combines tapping on acupressure points with counseling — can reduce anxiety, depression, pain, and insomnia in people with cholangiocarcinoma, a rare and aggressive bile duct cancer. Four…

This study tests an expanded web-based decision aid for people with cholangiocarcinoma, colorectal cancer, or multiple myeloma. Participants use the tool to choose which genomic results—such as cancer biomarkers or inherited risks—they want to receive. The goal is to see if the t…

The JADE study is a large registry that will follow 1,000 people with liver or bile duct cancer in Germany. Its goal is to collect information on how these cancers are actually treated in routine care, including treatments, outcomes, and patient quality of life. No experimental d…

This study aimed to review past cases of a treatment called radioembolization (using tiny radiation beads) for liver tumors, including a rare type of bile duct cancer. The goal was to understand how well it works and what risks it carries. However, the study was withdrawn before …

This study is testing a new blood test to see if it can find tiny bits of bile duct cancer left behind after treatment. Researchers will follow 100 adults who are having surgery to remove their cancer. The goal is to see if the test can predict if the cancer will come back sooner…

This study is a registry that collects information from patients who have a procedure called percutaneous cholangiopancreatoscopy (PCPS). During PCPS, doctors use a tiny camera to see inside the bile ducts and remove stones or take tissue samples. The goal is to learn how well th…

This study reviews medical records of 300 people diagnosed with choledochal cysts (bile duct cysts) between 2000 and 2020 in Western hospitals. The goal is to find out how often these cysts lead to bile duct cancer and what factors increase that risk. By analyzing symptoms, treat…

This study looks at whether a home-based exercise program is practical and safe for people aged 65 and older who are waiting for liver or bile duct cancer surgery. About 25 participants will do supervised exercise sessions and be tracked for how many join, stick with it, and repo…